Category: T-Cell Therapies

TIL Therapies: A New Paradigm in Cancer Treatment

Modified tumor-infiltrating lymphocytes or TIL therapies have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL-based therapies. Their tumor-cell killing efficiency is attributed to the fact that they are

TCR T Cell Therapy: An Emerging Therapeutic Modality

Modified T-cell receptors or TCR T cell therapy is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Structurally, TCR is a heterodimer comprising of two different polypeptide chains, namely the α-chain and β-chain. TCR therapies’ tumor-cell killing efficacy may be primarily attributed to the fact that they

Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders

The American Society of Gene and Cell Therapy (ASGCT) defines cell therapy as a therapeutic modality that involves the administration of either normal or modified cells to patients for the treatment of various diseases. In this form of therapy, patients are injected with living and intact human cells that are deemed to be capable of

CAR-T Cell Therapy: Addressing Key Unmet Needs in Oncology

Amidst the active initiatives undertaken to develop more targeted anti-cancer therapies, CAR-T therapies have emerged as a promising option, given their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Further, CAR-T cell therapy, relatively recent addition to the gamut of anticancer interventions, has demonstrated significant promise. Overall, this highly specific

Treg Cell Therapy: A Hotspot in the Field of Immunotherapy

Classification of Treg Cell Therapy The Treg cell therapy (Tregs) is a therapeutic modality based on the mature subpopulation of T-cell therapy that plays a critical role in mediating immunological tolerance to self-antigens and suppress immune responses that are harmful to the host, thereby, enabling homeostasis. These mainly develop in thymus from CD4+ thymocytes and

T-Cell Therapies Funding Update: Tmunity Raises $75 Million in Series B Funding

On 31st October 2019, Tmunity Therapeutics, a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell Therapies, announced the closing of $75 million Series B financing. Who were the key investors in T-cell Therapies: The financing was led by Andreessen Horowitz (also known as “a16z”). Joining the